Cumberland Pharmaceuticals
Cumberland Pharmaceuticals, headquartered in Nashville, TN, focuses on hospital acute care and gastroenterology markets, with a diverse product portfolio including Acetadote, Caldolor, and Kristalose. The company is listed on NASDAQ under CPIX and supports early-stage drug development through its subsidiary, Cumberland Emerging Technologies.
Company Overview
Cumberland Pharmaceuticals is a company focused on the hospital acute care and gastroenterology market segments. Headquartered at 1600 West End Avenue, Suite 1300, Nashville, TN 37203, Cumberland Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol CPIX. The company actively supports its mission through community involvement, ethical marketing, and drug safety policies.
Products
Cumberland Pharmaceuticals' product portfolio includes several treatments utilized in various medical conditions. Acetadote is an IV treatment for acetaminophen overdose. Caldolor, the first injectable therapy in the U.S. for both pain and fever. Kristalose is a branded prescription laxative in powder form. Vaprisol is an intravenously administered vasopressin receptor antagonist for hyponatremia. Omeclamox-Pak addresses Helicobacter pylori infection and related ulcers. Vibativ is an FDA-approved injectable antibiotic for serious bacterial infections. RediTrex is used for rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. Sancuso, a transdermal patch, treats nausea and vomiting in adults undergoing chemotherapy.
Research and Development
Cumberland Pharmaceuticals has a subsidiary, Cumberland Emerging Technologies (CET), which focuses on early-stage drug development. CET was established as a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University, and the state of Tennessee. CET manages a Life Sciences Center that provides laboratory and office space, equipment, and infrastructure to early-stage biomedical companies. The company has received FDA Orphan Drug Grant Funding for studying ifetroban in patients with Duchenne Muscular Dystrophy.
Facilities and Operations
Cumberland Pharmaceuticals recently moved into new headquarters at the Broadwest campus in the Vanderbilt/West End corridor of Nashville. CET operates a Life Sciences Center that offers laboratory and office spaces, as well as equipment and infrastructure support for early-stage biomedical companies. These facilities support Cumberland's focus on innovation and drug development.
FDA Approvals and Grants
Cumberland Pharmaceuticals has received multiple FDA approvals and grants. This includes FDA approval for Acetadote, Caldolor, RediTrex, and Vibativ. The company has also been granted FDA Orphan Drug Grant Funding for the study of ifetroban in patients with Duchenne Muscular Dystrophy. These approvals and grants underscore Cumberland’s commitment to developing effective treatments for serious medical conditions.